Explore an available treatment option for patients with HER2+ metastatic breast cancer
Introduction
Unmet need in HER2+ MBC
Efficacy and safety data from HER2CLIMB
Dosing and administration
Patient cases
Q&A
Meet the Speaker
Erika Hamilton, MD
Director of the Breast and Gynecologic
Research Program
Sarah Cannon Research Institute
Tiffany A. Traina, MD
Vice Chair, Oncology Care
Section Head, Triple Negative Breast Cancer
Clinical Research Program
Associate Attending Physician
Associate Professor
Weil Cornell Medical College
Charles E. Geyer, Jr., MD, FACP
Lois E. and Carl A. Davis Centennial Chair in Cancer Research
Houston Methodist Cancer Center
Program Objectives
Identify the unmet need and challenges in human epidermal growth factor receptor 2- postive (HER2+) metastatic breast cancer (MBC)
Explore expert insights and responses to questions from community practice
Review the key efficacy and safety data from HER2CLIMB trial
Review patient cases
SEA-20-OSV1039